Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.86% is 58% below its 5-year average of 13.79%, near the low end of its 5-year range (5.86%–107.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.88% below its 12-month average of 7.31%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.86%.
DEBT TO ASSETS RATIO
5.86%
DEBT TO ASSETS RATIO AVG TTM
7.31%
DEBT TO ASSETS RATIO AVG 3Y
10.83%
DEBT TO ASSETS RATIO AVG 5Y
13.79%
DEBT TO ASSETS RATIO AVG 10Y
10.08%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-19.88%
CURRENT VS 3Y AVG
-45.87%
CURRENT VS 5Y AVG
-57.50%
CURRENT VS 10Y AVG
-41.87%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 795 covered companies
CURRENT VS SECTOR MEDIAN
+6411.06%
vs the sector median at left
Pulse Biosciences, Inc.
Market Cap
$3.41B
Debt to Assets Ratio
5.86%
TTM Avg
7.31%
3Y Avg
10.83%
5Y Avg
13.79%
Market Cap
$3.39B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.48B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.49B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.32B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.55B
Debt to Assets Ratio
0.67%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.64B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulse Biosciences, Inc. (PLSE) | $3.41B | 5.86% | 7.31% | 10.83% | 13.79% |
| CareDx, Inc (CDNA)vs › | $3.40B | 0.04% | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 0.04% | N/A | N/A | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.48B | 0.00% | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.49B | 0.91% | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | 0.02% | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.32B | 0.04% | N/A | N/A | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 0.67% | N/A | N/A | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | 0.13% | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | 0.02% | N/A | N/A | N/A |
Debt/Assets
5.9%
Debt/Equity
0.07
Current Ratio
9.63
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.86% |
| 2026-03-31 | 8.77% |
| 2025-12-31 | 7.83% |
| 2025-09-30 | 7.25% |
| 2025-06-30 | 6.86% |
| 2025-03-31 | 6.43% |
| 2024-12-31 | 6.72% |
| 2024-09-30 | 8.99% |
| 2024-06-30 | 21.38% |
| 2024-03-31 | 18.10% |
| 2023-12-31 | 15.46% |
| 2023-09-30 | 14.23% |
| 2023-06-30 | 12.87% |
| 2023-03-31 | 107.71% |
| 2022-12-31 | 97.53% |
| 2022-09-30 | 86.03% |
| 2022-06-30 | 25.73% |
| 2022-03-31 | 26.89% |
| 2021-12-31 | 20.74% |
| 2021-09-30 | 17.99% |
| 2021-06-30 | 16.11% |
| 2021-03-31 | 65.02% |
| 2020-12-31 | 27.50% |
| 2020-09-30 | 23.04% |
| 2020-06-30 | 19.60% |
| 2020-03-31 | 21.32% |
| 2019-12-31 | 16.03% |
| 2019-09-30 | 7.91% |
| 2019-06-30 | 6.82% |
| 2019-03-31 | 2.55% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2014-12-31 | 0.00% |
